CELL AND GENE THERAPY WILL BE THE KEY DEVELOPMENT DIRECTION OF BEIJING'S PHARMACEUTICAL AND HEALTH INDUSTRY

IMMUNOTECH BIOPHARM LTD DEBUTED AT THE ZHONGGUANCUN FORUM WITH EAL, AND CEO DR. WANG YU GAVE A WONDERFUL PRESENTATION AT THE 2023 ZHONGGUANCUN INTERNATIONAL TECHNOLOGY TRADING CONFERENCE

TALKING ABOUT THE FRONTIERS OF CELL THERAPY INDUSTRY TOGETHER, STANDARDS EMPOWER SUSTAINABLE DEVELOPMENT OF ENTERPRISES

DISCUSSION ON THE KEY POINTS OF CMC RESEARCH IN VARIOUS STAGES OF INNOVATIVE DRUGS

SUMMARY | 46 GLOBALLY AVAILABLE GENE THERAPY DRUGS

THE DEVELOPMENT MOMENTUM OF CELL THERAPY IN CHINA IS STRONG, WITH 14 APPROVED CLINICAL PRODUCTS AND 24 NEWLY ACCEPTED PRODUCTS IN THE FIRST QUARTER

THE INDEPENDENT RESEARCH AND DEVELOPMENT INNOVATION AND INDUSTRIALIZATION OF BIOTECHNOLOGY AND BIG HEALTH INDUSTRIES IN BEIJING ECONOMIC-TECHNOLOGICAL DEVELOPMENT AREA "DOUBLE ACCELERATION"

DR. WANG YU, CEO OF YONGTAI BIO-B (06978. HK), ATTENDED THE BOAO FORUM FOR ASIA HEALTH INDUSTRY INTERNATIONAL FORUM - CELL GENE THERAPY AND INDUSTRIALIZATION DEVELOPMENT SUB FORUM AND DELIVERED A KEYNOTE SPEECH

WEEKLY NEWS OVERVIEW OF CELL GENE THERAPY INDUSTRY (~2023.4.17)

WEEKLY NEWS OVERVIEW OF CELL GENE THERAPY INDUSTRY (~2023.04.10)